Table 1.

Summary of published reports of minimal change disease associated with immune checkpoint inhibitors

	Authors, year	Age	Sex	Disease	ICPIs	Cr (baseline) (mg/dl)	Cr (worst) (mg/dl)	Proteinuria (pretreatment) (g/d)	Proteinuria (posttreatment) (g/d)	Treatment (/d)	Taper (days)	Outcome	Rechallenge
No Rechallenge	Bickel et al., 2016	62	M	Mesothelioma	Pembrolizumab	GFR 90	GFR 27	19	0	PSL 1 mg/kg	70	CR
	Kidd and Gizaw, 2016	55	M	Melanoma	Ipilimumab	1.2	5.2	9	NA	PSL 2 mg/kg	NA	CR
	Kitchlu et al., 2017	43	M	Hodgkin lymphoma	Pembrolizumab	0.76	3.93	10.3	3.1	PSL 2 mg/kg	180	PR
	Gao et al., 2018	40	M	Hodgkin lymphoma	SHR-1210 (anti−PD-1)	0.77	NA	30	0.18	PSL 1 mg/kg	56	CR
	Izzedine et al., 2019	NA	NA	Melanoma	Pembrolizumab	GFR 90	GFR 28	6	NA	PSL (NA) mg	NA	ESRD
	Izzedine et al., 2019	NA	NA	Ileal NETs	Pembrolizumab	NA	1.65	3.5	NA	No treatment	NA	SD
	E. Vaughan et al., 2020	57	M	Tongue squamous cell carcinoma	Nivolumab	0.79	2.29	2.1	NA	PSL 75 mg	NA	SD
Rechallenge	Kitchlu et al., 2017	45	M	Melanoma	Ipilimumab	0.68	0.8	9.5	0.39	PSL 1 mg/kg	120	CR	Recurrence without PSL
	Saito et al., 2019	79	M	Lung adenocarcinoma	Pembrolizumab	NA	NA	13.8	0	PSL 40 mg →10 mg	56	CR	No recurrence with PSL 10 mg/d
	Glutsh et al., 2019	68	M	Melanoma	Pembrolizumab	normal	2.86	19	0.33	PSL 100 mg	42	CR	Recurrence without PSL

CR, complete remission; ESRD, end-stage renal disease; GFR, glomerular filtration rate; ICPIs, immune checkpoint inhibitors; M, male; NA, not available, NETs, neuroendocrine tumors; PD-1, programmed death−1; PR, partial response; PSL, prednisolone; SD, stable disease.